Primary HIV-1 Infection: Diagnosis, Pathogenesis, and Treatment

Overview

Journal Curr Infect Dis Rep

Specialty Infectious Diseases

Date 2005 Feb 25

PMID 15727743

Citations 1

Authors

Malini Soogoor

Eric S Daar

Affiliations

Soon will be listed here.

Abstract

Primary HIV-1 infection represents the time when the virus is first disseminating throughout the body and induces host immune responses. Diagnosing this stage of disease requires an understanding of who is at risk, the clinical manifestations of primary infection, and how the diagnosis is made. Identifying these individuals allows for counseling to prevent further transmission to others and the potential benefits associated with early antiretroviral therapy. Moreover, studying these individuals provides important insight into the biology of HIV-1 transmission and immunopathogenesis.

Citing Articles

Clinical and immunological status of a newly diagnosed HIV positive population, in Marrakech, Morocco.

Admou B, Elharti E, Oumzil H, Addebbous A, Amine M, Zahlane K Afr Health Sci. 2011; 10(4):325-31.

PMID: 21416033 PMC: 3052800.

References

Kinloch-De Loes S, Hirschel B, Hoen B, Cooper D, Tindall B, Carr A . A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med. 1995; 333(7):408-13. DOI: 10.1056/NEJM199508173330702. View

Koup R, Safrit J, Cao Y, Andrews C, McLeod G, Borkowsky W . Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994; 68(7):4650-5. PMC: 236393. DOI: 10.1128/JVI.68.7.4650-4655.1994. View

Hecht F, Busch M, Rawal B, Webb M, Rosenberg E, Swanson M . Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS. 2002; 16(8):1119-29. DOI: 10.1097/00002030-200205240-00005. View

Schiffer V, Deveau C, Meyer L, Iraqui I, Nguyen-Wartel A, Chaix M . Recent changes in the management of primary HIV-1 infection: results from the French PRIMO cohort. HIV Med. 2004; 5(5):326-33. DOI: 10.1111/j.1468-1293.2004.00231.x. View

Blower S, Aschenbach A, Kahn J . Predicting the transmission of drug-resistant HIV: comparing theory with data. Lancet Infect Dis. 2002; 3(1):10-1. DOI: 10.1016/s1473-3099(03)00479-1. View

Miller J, Carr A, Smith D, Emery S, Law M, Grey P . Lipodystrophy following antiretroviral therapy of primary HIV infection. AIDS. 2000; 14(15):2406-7. DOI: 10.1097/00002030-200010200-00025. View

Forthal D, Landucci G, Daar E . Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol. 2001; 75(15):6953-61. PMC: 114423. DOI: 10.1128/JVI.75.15.6953-6961.2001. View

Constantine N, Sill A, Jack N, Kreisel K, Edwards J, Cafarella T . Improved classification of recent HIV-1 infection by employing a two-stage sensitive/less-sensitive test strategy. J Acquir Immune Defic Syndr. 2003; 32(1):94-103. DOI: 10.1097/00126334-200301010-00014. View

Musey L, Hughes J, Schacker T, Shea T, Corey L, McElrath M . Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med. 1997; 337(18):1267-74. DOI: 10.1056/NEJM199710303371803. View

10.

Barbour J, Hecht F, Wrin T, Liegler T, Ramstead C, Busch M . Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS. 2004; 18(12):1683-9. DOI: 10.1097/01.aids.0000131391.91468.ff. View

11.

Sagar M, Lavreys L, Baeten J, Richardson B, Mandaliya K, Chohan B . Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression. J Virol. 2003; 77(23):12921-6. PMC: 262567. DOI: 10.1128/jvi.77.23.12921-12926.2003. View

12.

Pilcher C, McPherson J, Leone P, Smurzynski M, Owen-ODowd J, Harris J . Real-time, universal screening for acute HIV infection in a routine HIV counseling and testing population. JAMA. 2002; 288(2):216-21. DOI: 10.1001/jama.288.2.216. View

13.

Rizzardi G, Harari A, Capiluppi B, Tambussi G, Ellefsen K, Ciuffreda D . Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest. 2002; 109(5):681-8. PMC: 150896. DOI: 10.1172/JCI14522. View

14.

Rosenberg E, Billingsley J, Caliendo A, Boswell S, Sax P, Kalams S . Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science. 1997; 278(5342):1447-50. DOI: 10.1126/science.278.5342.1447. View

15.

Delwart E, Magierowska M, Royz M, Foley B, Peddada L, Smith R . Homogeneous quasispecies in 16 out of 17 individuals during very early HIV-1 primary infection. AIDS. 2002; 16(2):189-95. DOI: 10.1097/00002030-200201250-00007. View

16.

Montefiori D, Altfeld M, Lee P, Bilska M, Zhou J, Johnston M . Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual. J Immunol. 2003; 170(7):3906-14. DOI: 10.4049/jimmunol.170.7.3906. View

17.

Burchell A, Calzavara L, Ramuscak N, Myers T, Major C, Rachlis A . Symptomatic primary HIV infection or risk experiences? Circumstances surrounding HIV testing and diagnosis among recent seroconverters. Int J STD AIDS. 2003; 14(9):601-8. DOI: 10.1258/095646203322301059. View

18.

Vanhems P, Dassa C, Lambert J, Cooper D, Perrin L, Vizzard J . Comprehensive classification of symptoms and signs reported among 218 patients with acute HIV-1 infection. J Acquir Immune Defic Syndr. 1999; 21(2):99-106. View

19.

Richters J, Grulich A, Ellard J, Hendry O, Kippax S . HIV transmission among gay men through oral sex and other uncommon routes: case series of HIV seroconverters, Sydney. AIDS. 2003; 17(15):2269-71. DOI: 10.1097/00002030-200310170-00020. View

20.

Tremblay C, Hicks J, Sutton L, Giguel F, Flynn T, Johnston M . Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection. AIDS. 2003; 17(7):1086-9. DOI: 10.1097/00002030-200305020-00021. View